Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: CPark who wrote (56125)	5/2/2020 4:27:28 PM
From: TinfoilHat	19 Recommendations Read Replies (1) of 63277

Dr DorightbyallofUs inspired me to lookup this data, which I had not previously found. Pretty remarkable, confirms my suspicion that SG aka Trodelvy will most likely work in HER2+ BC, and definitely in HR+ Tropics2. Whichever analysts still doubt this should start covering those shorts. This is a meta analysis of 4 trials with over 3000 patients combined. ascopubs.org Conclusions: Trop2e (expression) is seen in all BC (breast cancer) subtypes, particularly luminal A (ie, HR+) and TNBC. Trop2e correlates with the expression of genes involved in cell epithelial transformation, adhesion, and proliferation and inversely with immune genes (this sentence describes potential to combine SG with certain other targeted therapies), which may contribute to tumor growth. These findings support the use of trop 2 directed ADC in all BC subtypes. The most astute of key opinion leaders will read this last sentence and consider Trodelvy as salvage therapy after all other options have been exhausted, noting that 42k women die of breast cancer in the US every year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next